MX2016012104A - Compuestos de azabenzofurano que contienen ciano para el tratamiento de la hepatitis c. - Google Patents

Compuestos de azabenzofurano que contienen ciano para el tratamiento de la hepatitis c.

Info

Publication number
MX2016012104A
MX2016012104A MX2016012104A MX2016012104A MX2016012104A MX 2016012104 A MX2016012104 A MX 2016012104A MX 2016012104 A MX2016012104 A MX 2016012104A MX 2016012104 A MX2016012104 A MX 2016012104A MX 2016012104 A MX2016012104 A MX 2016012104A
Authority
MX
Mexico
Prior art keywords
compounds
hepatitis
treatment
cyano containing
azabenzofuran
Prior art date
Application number
MX2016012104A
Other languages
English (en)
Inventor
F Kadow John
Wang Tao
J Eastman Kyle
Zhang Zhongxing
E Parcella Kyle
Yin Zhiwei
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2016012104A publication Critical patent/MX2016012104A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos de la Fórmula I, que incluyen sus sales, además de composiciones y métodos para usar los compuestos. Los compuestos tienen actividad contra el virus de la hepatitis C (HCV) y pueden ser útiles en el tratamiento de los pacientes infectados con HCV. (ver Fórmula).
MX2016012104A 2014-03-21 2015-03-20 Compuestos de azabenzofurano que contienen ciano para el tratamiento de la hepatitis c. MX2016012104A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461968763P 2014-03-21 2014-03-21
PCT/US2015/021638 WO2015143255A1 (en) 2014-03-21 2015-03-20 Cyano containing azabenzofuran compounds for the treatment of hepatitis c

Publications (1)

Publication Number Publication Date
MX2016012104A true MX2016012104A (es) 2016-12-09

Family

ID=52808191

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012104A MX2016012104A (es) 2014-03-21 2015-03-20 Compuestos de azabenzofurano que contienen ciano para el tratamiento de la hepatitis c.

Country Status (18)

Country Link
US (1) US9249152B2 (es)
EP (1) EP3119785B1 (es)
JP (1) JP2017509700A (es)
KR (1) KR20160126085A (es)
CN (1) CN106459070A (es)
AR (1) AR099820A1 (es)
AU (1) AU2015231139A1 (es)
CA (1) CA2943526A1 (es)
CL (1) CL2016002361A1 (es)
EA (1) EA201691777A1 (es)
ES (1) ES2688554T3 (es)
IL (1) IL247830A0 (es)
MX (1) MX2016012104A (es)
PE (1) PE20161224A1 (es)
SG (1) SG11201607750PA (es)
TW (1) TW201620914A (es)
WO (1) WO2015143255A1 (es)
ZA (1) ZA201606478B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9920036B2 (en) * 2014-03-21 2018-03-20 Bristol-Myers Squibb Company Cyanoamino (aza)benzofuran compounds for the treatment of hepatitis C
MX2018006856A (es) * 2015-12-07 2018-08-01 Plexxikon Inc Compuestos y metodos para modulacion de la quinasa, e indicaciones de los mismos.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041201A2 (en) 2002-11-01 2004-05-21 Viropharma Incorporated Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
ES2377280T3 (es) 2008-02-14 2012-03-26 F. Hoffmann-La Roche Ag Compuestos heterocíclicos antivíricos
US7994171B2 (en) * 2008-09-11 2011-08-09 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8198449B2 (en) * 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8048887B2 (en) * 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2545050B1 (en) * 2010-03-10 2014-08-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
US20130302282A1 (en) 2010-10-26 2013-11-14 Presidio Pharmaceuticals, Inc. Inhibitors of Hepatitis C Virus

Also Published As

Publication number Publication date
TW201620914A (zh) 2016-06-16
CN106459070A (zh) 2017-02-22
ZA201606478B (en) 2018-05-30
CL2016002361A1 (es) 2017-04-21
JP2017509700A (ja) 2017-04-06
WO2015143255A1 (en) 2015-09-24
EP3119785B1 (en) 2018-08-15
PE20161224A1 (es) 2016-11-12
AR099820A1 (es) 2016-08-17
KR20160126085A (ko) 2016-11-01
CA2943526A1 (en) 2015-09-24
AU2015231139A1 (en) 2016-11-03
IL247830A0 (en) 2016-11-30
US20150266886A1 (en) 2015-09-24
SG11201607750PA (en) 2016-10-28
EP3119785A1 (en) 2017-01-25
US9249152B2 (en) 2016-02-02
ES2688554T3 (es) 2018-11-05
EA201691777A1 (ru) 2016-12-30

Similar Documents

Publication Publication Date Title
JOP20170130A1 (ar) مركبات لمعالجة عدوى فيروس التهاب الكبد الوبائي b
PH12016501254A1 (en) Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
EA201691726A1 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
JOP20180008A1 (ar) مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
NZ724503A (en) Macrocyclic inhibitors of flaviviridae viruses
PH12014502739A1 (en) Macrocyclic inhibitors of flaviviridae viruses
MX2012004032A (es) Compuestos para el tratamiento de hepatitis c.
NZ703066A (en) Macrocyclic inhibitors of flaviviridae viruses
PH12014500557A1 (en) Methods for treating hcv
MX2017000312A (es) Derivados de isoindolina para usarse en el tratamiento de una infeccion viral.
MX2016004492A (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana (vih).
PH12013501543A1 (en) Hepatitis c virus inhibitors
PH12015502230A1 (en) Novel viral replication inhibitors
MX2021004464A (es) Compuestos de tiazolida para el tratamiento de infecciones virales.
PH12014500385A1 (en) Benzofuran compounds for the treatment of hepatitis c virus infections
EA201692550A1 (ru) Соединения, содержащие систему 1,1',2,5'-тетрагидроспиро[индол-3,2'-пиррол]-2,5'-диона в качестве ингибиторов белок-белкового взаимодействия p53-mdm2
WO2014116772A3 (en) Squaric derivatives for the treatment of hepatitis c
MX2010010061A (es) Compuestos para el tratamiento de hepatitis c.
MX2016012104A (es) Compuestos de azabenzofurano que contienen ciano para el tratamiento de la hepatitis c.
TW201613939A (en) Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
TN2011000089A1 (en) Compounds for the treatment of hepatitis c
EA201892348A1 (ru) Комбинации и способы, включающие ингибитор сборки капсида
MY163245A (en) Hepatitis c virus inhibitors
TH149188A (th) สารยับยั้งไวรัสตับอักเสบ c
TN2013000335A1 (en) Hepatitis c virus inhibitors